Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2002 Nov;19(11):1599-605.
doi: 10.1023/a:1020989709019.

In vivo characteristics of cationic liposomes as delivery vectors for gene therapy

Affiliations
Review

In vivo characteristics of cationic liposomes as delivery vectors for gene therapy

Sandrine A L Audouy et al. Pharm Res. 2002 Nov.

Abstract

After a decade of clinical trials, gene therapy seems to have found its place between excessive ambitions and feasible aims, with encouraging results obtained in recent years. Intracellular delivery of genetic material is the key step in gene therapy. Optimization of delivery vectors is of major importance for turning gene therapy into a successful therapeutic method. Nonviral gene delivery relies mainly on the complexes formed from cationic liposomes (or cationic polymers) and DNA, i.e., lipoplexes (or polyplexes). Many lipoplex formulations have been studied, but in vivo activity is generally low compared to that of viral systems. This review gives a concise overview of studies on the application of cationic liposomes in vivo in animal models of diseases and in clinical studies. The transfection efficiency, the pharmacokinetic and pharmacodynamic properties of the lipid-DNA complexes, and potentially relevant applications for cationic liposomes are discussed. Furthermore, the toxicity of, and the induction of an inflammatory response in association with the administration of lipoplexes are described. Increasing understanding of lipoplex behavior and gene transfer capacities in vivo offers new possibilities to enhance their efficiency and paves the path to more extensive clinical applications in the future.

PubMed Disclaimer

Similar articles

Cited by

References

    1. Pharm Res. 2000 May;17(5):521-5 - PubMed
    1. Hum Gene Ther. 1998 Sep 20;9(14):2083-99 - PubMed
    1. Cancer Gene Ther. 2000 Jun;7(6):853-60 - PubMed
    1. Hum Gene Ther. 1997 Mar 1;8(4):431-8 - PubMed
    1. Hum Gene Ther. 2001 May 1;12(7):799-809 - PubMed

LinkOut - more resources